These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30819908)

  • 1. Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation.
    Zafrani L; Dekimpe C; Joly BS; Roose E; Fieux F; Azoulay E; Peraldi MN; Durrbach A; Coppo P; Vanhoorelbeke K; Veyradier A
    Haematologica; 2019 Jun; 104(6):e277-e280. PubMed ID: 30819908
    [No Abstract]   [Full Text] [Related]  

  • 2. Familial acquired thrombotic thrombocytopenic purpura in siblings - no immunogenetic link with associated human leucocyte antigens.
    Gödel P; Fischer J; Scheid C; Gathof BS; Wolf J; Rybniker J
    Eur J Haematol; 2017 Mar; 98(3):311-313. PubMed ID: 27859681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
    Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL
    Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic thrombocytopenic purpura: The role of ADAMTS13.
    Rogers HJ; Allen C; Lichtin AE
    Cleve Clin J Med; 2016 Aug; 83(8):597-603. PubMed ID: 27505881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
    Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies.
    Smock KJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():103-108. PubMed ID: 34288437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.
    Page EE; Kremer Hovinga JA; Terrell DR; Vesely SK; George JN
    Blood; 2016 Oct; 128(17):2175-2178. PubMed ID: 27625362
    [No Abstract]   [Full Text] [Related]  

  • 9. Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission.
    Stubbs MJ; Thomas M; Vendramin C; Sonesson E; Kjellman C; Järnum S; Stenberg Y; Elfving C; Scully M
    Br J Haematol; 2019 Jul; 186(1):137-140. PubMed ID: 30488420
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitory anti ADAMTS13 antibodies with a new rapid fully automated CLiA assay.
    Montaruli B; Novelli C; Solfietti L; Valpreda A; Bazzan M; Luigi Andrea Beverina I; Brando B; Roccatello D; Cosseddu D
    Int J Lab Hematol; 2021 Apr; 43(2):298-304. PubMed ID: 33095979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
    Mariotte E; Azoulay E; Galicier L; Rondeau E; Zouiti F; Boisseau P; Poullin P; de Maistre E; Provôt F; Delmas Y; Perez P; Benhamou Y; Stepanian A; Coppo P; Veyradier A;
    Lancet Haematol; 2016 May; 3(5):e237-45. PubMed ID: 27132698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.
    Alwan F; Vendramin C; Vanhoorelbeke K; Langley K; McDonald V; Austin S; Clark A; Lester W; Gooding R; Biss T; Dutt T; Cooper N; Chapman O; Cranfield T; Douglas K; Watson HG; van Veen JJ; Sibson K; Thomas W; Manson L; Hill QA; Benjamin S; Ellis D; Westwood JP; Thomas M; Scully M
    Blood; 2017 Jul; 130(4):466-471. PubMed ID: 28576877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
    Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F;
    Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding therapeutic targets in thrombotic thrombocytopenic purpura.
    Joly BS; Vanhoorelbeke K; Veyradier A
    Intensive Care Med; 2017 Sep; 43(9):1398-1400. PubMed ID: 28116452
    [No Abstract]   [Full Text] [Related]  

  • 15. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
    Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
    Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.
    Schelpe AS; Roose E; Joly BS; Pareyn I; Mancini I; Biganzoli M; Deckmyn H; Voorberg J; Fijnheer R; Peyvandi F; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K
    Haematologica; 2019 Jun; 104(6):1268-1276. PubMed ID: 30523052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13.
    Saeki T; Ito T; Youkou A; Ishiguro H; Sato N; Yamazaki H; Koike T; Kourakata H; Ferrari S; Scheiflinger F; Narita I
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1209-12. PubMed ID: 21523922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.